Robert L. Ferris, MD, PhD | Authors


Excitement Shown With New NCI Director But Uncertainty Looms at Launch of the ARPA-H Institute

October 19, 2022

The oncology community has enjoyed success to a large degree through the existing NIH and NCI mechanisms. Will they ask how can they work with us in a concerted fashion to benefit new discoveries, novel translation in well-designed clinical trials, and eventual development of exciting, more effective cancer therapies for patients?

Promising Findings From DESTINY-Breast04 Trial Energizes ASCO Meeting

July 22, 2022

Harnessing existing and otherwise safe antibody-targeting strategies and combining them with chemotherapy or other bioactive compounds or as a bispecific dual antibody moiety are an exciting strategy of protein engineering that is emerging and coming into its own in oncology.